Delaware court refuses to enforce Fresenius/Akorn merger agreement
A judge has ruled that healthcare company Fresenius was entitled to pull out of a planned $4.75 billion takeover of generic drugmaker Akorn, after finding that the target made false representations about the state of its data.
To read more
Subscribe to Global Data Review
Subscribe & start reading now!
The one-stop information source and community touchpoint, with coverage from across the areas of
- Data protection
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10